Stephen’s most recent role was Group Communications Director at Prudential PLC and he has previously held senior leadership roles at Barclays PLC and Allied Domecq PLC. He has a strong personal passion and commitment to the pharmaceutical industry and earlier in his career spent ten years at Glaxo and Eli Lilly at UK, European and international level. Stephen has in-depth experience of working in regulated industries, has led significant change and modernisation programmes and has extensive experience of developing high performing teams.
ABPI President Simon Jose said: 'The Board of Management is delighted by this appointment. We are in a time of dynamic change for the health service, the economy, our industry and the ABPI itself. As chief executive, Stephen brings skills and experiences that will enable us to meet the challenges ahead with energy and creativity. His expertise in effective stakeholder relations acquired over a 25 year career in policy, public affairs and communications will provide effective leadership to ensure we work in partnerships that benefit patients, the NHS and the pharmaceutical industry.
Stephen Whitehead said: 'I am hugely excited to be appointed to the role of Chief Executive at the ABPI and am very much looking forward to bringing fresh ideas to its modernisation agenda. In today’s changing environment and demanding economic circumstances it will be essential to work collaboratively and flexibly to realise the value of medicines in contributing to patients’ well-being and to promote the vital importance of this industry in the UK, a traditional home of discovery, innovation and research and development.
Stephen’s appointment follows a vigorous recruitment process involving an extensive search led by an external agency and a six member appointment panel representing the ABPI Board. Director General, Richard Barker, steps down on 25 May.
For further information, please contact: ABPI Press Office 020 7747 1410